P2X receptor antagonists for pain management: Examination of binding and physicochemical properties

Purinergic Signalling

Volumn 8, Issue SUPPL. 1, 2012, Pages 41-56

  Gum, Rebecca J ^a   Wakefield, Brian ^a   Jarvis, Michael F ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

P2X3; P2X4; P2X7; Pain; Physicochemical parameters

Indexed keywords

EID: 84856274262     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-011-9272-5     Document Type: Review

References (95)

1. Honore P, Jarvis MF (2006) Acute and chronic pain. In: Triggle DJ, Taylor JB (eds) Comprehensive medicinal chemistry II, vol. 6. Elsevier, Oxford, pp 327-349.
2. Perl ER (2007) Ideas about pain, a historical view. Nat Rev Neurosci 8: 71-80.
3. Woolf CJ (2011) Central sensitization: implications for the diagnosis and treatment of pain. Pain 152(3 Suppl): S2-S15.
4. Basbaum AI, Bautista DM, Scherrer G, Julius D (2009) Cellular and molecular mechanisms of pain. Cell 139: 267-284.
5. Burnstock G (2007) Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 87: 659-797.
6. Bleehen T, Keele CA (1977) Observation on the algogenic actions of adenosine compounds on the human blister base preparation. Pain 3: 367-377.
7. Hamilton SG, Warburton J, Bhattacharjee A, Ward J, McMahon SB (2000) ATP in human skin elicits a dose-related pain response under conditions of hyperalgesia. Brain 123: 1238-1246.
8. Sawynok J (2007) Adenosine and ATP receptors. Handb Exp Pharmacol 177: 309-328.
9. 3 allosteric modulator, cibacron blue. Br J Pharmacol 132: 259-269.
10. Jacobson KA, Jarvis MF, Williams M (2002) Purine and pyrimidine (P2) receptors as drug targets. J Med Chem 45: 4057-4093.
11. Jarvis MF (2010) The neural-glial purinergic receptor ensemble in chronic pain states. Trends Neurosci 33: 48-57.
12. Mio K, Ogura T, Yamamoto T, Hiroaki Y, Fujiyoshi Y, Kubo Y, Sato C (2009) Reconstruction of the P2X(2) receptor reveals a vase-shaped structure with lateral tunnels above the membrane. Structure 17(2): 266-275.
13. Kawate T, Michel JC, Birdsong WT, Gouaux E (2009) Crystal structure of the ATP-gated P2X4 ion channel in the closed state. Nature 460: 592-598.
14. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability of drug discovery and development settings. Adv Drug Delivery Rev 46: 3-26.
15. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev/Drug Disc 6: 881-889.
16. Muresan S, Sadowski J (2008) Properties guiding drug- and lead-likeness. In: Mannhold R (ed) Molecular drug properties, measurement and prediction (Ch. 17). Wiley, Weinheim, pp 441-461.
17. Paolini GV, Shapland RHB, van Hoorn WP, Mason JS, Hopkins AL (2006) Global mapping of pharmacological space. Nat Biotech 24(7): 805-815.
18. Wenlock MC, Austin RP, Barton P, Davis AM, Leeson PD (2003) A comparison of physiochemical property profiles of development and marketed oral drugs. J Med Chem 46: 1250-1256.
19. Johnson TW, Dress KR, Edwards M (2009) Using the golden triangle to optimize clearance and oral absorption. Bioorg Med Chem Lett 19: 5560-5564.
20. Ritchie TJ, Macdonald SJF (2008) The impact of aromatic ring count on compound developability-are too many aromatic rings a liability in drug design? Drug Disc Today 14(21/22): 1011-1020.
21. Peters J, Schnider P, Mattei P, Kansy M (2009) Pharmacology promiscuity: dependence on compound properties and target specificity in a set of recent roche compounds. Chem Med Chem 4: 680-686.
22. Hughes JD, Blagg J, Price DA, Bailey S, DeCrescenzo GA, Devraj RV, Ellsworth E, Fobian YM, Gibbs ME, Gilles RW, Greene N, Huang E, Krieger-Burke T, Joesel J, Wager T, Whiteley L, Zhang Y (2008) Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg & Med Chem Lett 18: 4872-4875.
23. Wager TT, Chandrasekaran RY, Hou X, Troutman MD, Verhoest PR, Villalobos A, Will Y (2010) Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci 1: 420-434.
24. Wager TT, Hou X, Verhoest PR, Villalobos A (2010) Moving beyond Rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci 1: 435-449.
25. Abad-Zapatero C, Metz JT (2005) Ligand efficiency indices as guideposts for drug discovery. Drug Disc Today 10(7): 464-469.
26. Jarvis MF (2003) Contributions of P2X3 homomeric and heteromeric channels to acute and chronic pain. Expert Opin Ther Targets 7: 513-522.
27. Inoue K, Tsuda M, Tozaki-Saitoh H (2007) Modification of neuropathic pain sensation through microglial ATP receptor. Purinergic Sig 3: 311-316.
28. Martucci C, Trovato AE, Costa B, Borsani E, Franchi S, Magnaghi V, Panerai AE, Rodella LF, Valsecchi AE, Sacerdote P, Colleoni M (2008) The purinergic antagonist PPADS reduces pain related behaviors and interleukin-1beta, interleukin-6, iNOS and nNOS overproduction in central and peripheral nervous system after peripheral neuropathy in mice. Pain 137: 81-95.
29. Lewis CJ, Surprenant A, Evans RJ (1998) 2′, 3′-O-(2, 4, 6-trinitrophenyl)ATP- a nanomolar affinity antagonist at rat mesenteric artery P2X receptor ion channels. Br J Pharmacol 124: 1463-1466.
30. North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82: 1013-1067.
31. Donnelly-Roberts D, McGaraughty S, Shieh C-C, Honore P, Jarvis MF (2008) Painful purinergic receptors. J Pharm Exp Ther 324(2): 409-415.
32. Jarvis MF, Burgard EC, McGaraughty S, Honore P, Lynch K, Brennan TJ, Subieta A, van Biesen T, Cartmell J, Bianchi B, Niforatos W, Kage K, Yu H, Mikusa J, Wismer CT, Zhu CZ, Chu K, Lee CH, Stewart AO, Polakowski J, Cox BF, Kowaluk E, Williams M, Sullivan J, Faltynek C (2002) A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci USA 99: 17179-17184.
33. McGaraughty S, Wismer CT, Zhu CZ, Mikusa J, Honore P, Chu KL, Lee CH, Faltynek CR, Jarvis MF (2003) Effects of A-317491, a novel and selective P2X3/P2X2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration. Br J Pharmacol 140: 1381-1388.
34. Nakagawa T, Wakamatsu K, Zhang N, Maeda S, Minami M, Satoh M, Kaneko S (2007) Intrathecal administration of ATP produces long-lasting allodynia in rats: differential mechanisms in the phase of the induction and maintenance. Neuroscience 147: 445-455.
35. Gever JR, Cockayne DA, Dillon MP, Burnstock G, Ford APDW (2006) Pharmacology of P2X channels. Eur J Physiol 452: 513-537.
36. Carter DS, Alam M, Cai H, Dillon MP, Ford APDW, Gever JR, Jahangir A, Lin C, Moore AG, Wagner PJ, Zhai Y (2009) Identification and SAR of novel diaminopyrimidines. Part 1: the discovery of RO-4, a dual P2X3/P2X2/3 antagonist for the treatment of pain. Bioorg Med Chem Lett 19: 1628-1631.
37. Burgey CS (2011) Discovery of P2X3 receptor antagonists for the treatment of chronic pain. In: 241st ACS national meeting & exposition, Anaheim, CA, 27-31 March. MEDI-15.
38. Cantin L, Bayrakdarian M, Buon C, Hu Y, Kennedy V, Laplante M, Leung C, Luo X, Popovic N, Rene O, Santhakumar V, Butterworth J, Godbout C, Gosselin M, Grazzini E, Labrecque J, Pare M, Projean D, Yu XH, Tomaszewski MJ (2010) Pyrrolopyrimidine-based P2X3 antagonists for the treatment of pain. In: 240th ACS national meeting, Boston, MA, 2-26 August. MEDI-474.
39. Gever JR, Soto R, Henningsen RA, Martin RS, Hackos DH, Panicker S, Rubas W, Oglesby IB, Dillon MP, Mila ME, Burnstock G, Ford APDW (2010) AF-353 a novel potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol 160: 1387-1398.
40. Raouf R, Chabot-Doré AJ, Ase AR, Blais D, Séguéla P (2007) Differential regulation of microgial P2X4 and P2X7 ATP receptors following LPS-induced activation. Neuropharmacol 53: 496-504.
41. Inoue K (2006) The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol Ther 109: 210-226.
42. Horvath RJ, DeLeo JA (2009) Morphine enhances microglial migration through modulation of P2X4 receptor signaling. J Neurosci 29: 998-1005.
43. Tsuda M, Toyomitsu E, Komatsu T, Masuda T, Kunifusa E, Nasu-Tada K, Koizumi S, Yamamoto K, Ando J, Inoue K (2008) Fibronectin/integrin system is involved in P2X(4) receptor upregulation in the spinal cord and neuropathic pain after nerve injury. Glia 56: 579-585.
44. Tsuda M, Tozaki-Saitoh H, Masuda T, Toyomitsu E, Tezuka T, Yamamoto T, Inoue K (2008) Lyn tyrosine kinase is required for P2X4 receptor upregulation and neuropathic pain after peripheral nerve activation. Glia 56: 50-58.
45. Ulmann L, Hatcher JP, Hughes JP, Chaumont S, Green PJ, Conquet F, Buell GN, Reeve AJ, Chessell IP, Rassendren F (2008) Up-Regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain. J Neurosci 28: 11263-11268.
46. Coull JA, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, Gravel C, Salter MW, De Koninck Y (2005) BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438: 1017-1021.
47. Coull JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sik A, De Koninck P, De Koninck Y (2003) Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature 424: 938-942.
48. Trang T, Beggs S, Wan X, Salter MW (2009) P2X4 receptor mediated synthesis and release of brain derived neurotrophic factor in microglia is dependent on calcium and p38-MAPK. J Neurosci 29: 3518-3528.
49. Bernier LP, Ase AR, Chevallier S, Blais D, Zhao Q, Boué-Grabot E, Logothetis D, Séguéla P (2008) Phosphoinositides regulate P2X4 ATP-gated channels through direct interactions. J Neurosci 28: 12938-12945.
50. Jarvis MF, Khakh BS (2009) ATP-gated P2X cation-channels. Neuropharmacol 56: 208-215.
51. Khakh BS, North RA (2006) P2X receptors as cell-surface ATP sensors in health and disease. Nature 442: 527-532.
52. Muller CE (2010) Emerging structures and ligands for P2x3 AND P2X4 receptors-towards novel treatments of neuropathic pain. Purinergic Signalling 6: 145-148.
53. Ferrari D, Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, DiVirgilio F (2006) The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 176: 3877-3883.
54. MacKenzie A, Wilson HL, Kiss-Tosh E, Dower SK, North RA, Surprenant A (2001) Rapid secretion of interleukin-1β by microvesicle shedding. Immunity 8: 825-835.
55. Perregaux DG, Gabel CA (1994) Interleukin-1β maturation and release in response to ATP and nigericin. J Biol Chem 269: 15195-15203.
56. DiVirgilio F (2006) Purinergic signalling between axons and microglia. In: Chadwick DJ, Goode J (eds) Purinergic signalling in neuron-glia interactions. No. 276. Wiley, Chichester, pp 253-262.
57. Pelegrin P, Surprenant A (2009) The P2X7 receptor-pannexin connection to dye uptake and IL-1beta release. Purinergic Sig 5: 129-137.
58. 7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol 168: 6436-6445.
59. 7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114: 386-396.
60. Wolf G, Yirmiya R, Goshen I, Iverfeldt K, Holmlund L, Takeda K, Shavit Y (2004) Impairment of interleukin-1 (IL-1) signaling reduces basal pain sensitivity in mice: genetic, pharmacological and developmental aspects. Pain 104: 471-480.
61. Honore P, Wade CL, Zhong C, Harris RR, Wu C, Ghayur T, Iwakura Y, Decker MW, Faltynek C, Sullivan J, Jarvis MF (2006) Interleukin-1ab gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain. Behav Br Res 167: 355-364.
62. Guile SD, Alcaraz L, Birkinshaw TN, Bowers KC, Ebden MR, Furber M, Stocks MJ (2009) Antagonists of the P2X7 receptor. From lead identification to drug development. J Med Chem 52: 3123-3141.
63. 7 receptor function and indicates a role in chronic pain states. Br J Pharmacol 151: 571-579.
64. Donnelly-Roberts D, Namovic MT, Han P, Jarvis MF (2009) Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol 157: 1203-1214.
65. Beigi RD, Kertesy SB, Aquilina G, Dubyak GR (2003) Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor independent mechanisms. Br J Pharmacol 140: 507-519.
66. Jo S, Bean BP (2011) Inhibition of neuronal voltage-gated sodium channels by brilliant blue g. Mol Pharmacol 80(2): 247-257.
67. 7 receptor antagonist dose-dependently reduces neuropathic pain in the rat. J Pharmacol Exp Ther 319: 1376-1385.
68. 7 antagonists. J Med Chem 49: 3659-3666.
69. 7-related modulation of pathological nociception in rats. Neuroscience 146: 1817-1828.
70. Broom DC, Matson DJ, Bradshaw E, Buck ME, Meade R, Coombs S, Matchett M, Ford KK, Yu W, Yuan J, Sun SH, Ochoa R, Krause JE, Wustrow DJ, Cortright DN (2008) Characterization of N-(adamantan-1-ylmethyl)-5-((3R-amino-pyrrolidin-1-yl)methyl)-2-chloro-benzamide, a P2X7 antagonist in animal models of pain and inflammation. J Pharm Exper Ther 327(3): 620-633.
71. Furber M, (2008) P2X7 antagonists in a rheumatoid arthritis pain model. In: ACS national meeting, Philadelphia, PA. MEDI 237.
72. Honore P, Donnelly-Roberts D, Namovic M, Zhong C, Wade C, Chandran P, Zhu C, Carroll W, Perez-Medrano A, Iwakura Y, Jarvis MF (2009) The anti-hyperalgesic effects of a selective P2X7 receptor antagonist are lost in IL-1ab knockout mice. Behav Br Res 204: 77-81.
73. Hansen RR, Nielsen CK, Nasser A, Thomsen SIM, Eghorn LF, Pham Y, Schulenburg C, Syberg S, Ding M, Stojilkovic SS, Jorgensen NR, Heegaard AM (2011) P2X7 receptor deficient mice are susceptible to bone cancer pain. Pain 152: 1766-1776.
74. Pajouhesh H, Lenz GR (2005) Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2: 541-553.
75. Friden M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M (2009) Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 52: 6233-6243.
76. Hitchcock SA (2008) Blood-brain barrier permeability considerations for CNS-targeted compound library design. Curr Op Chem Biol 12: 318-323.
77. Blakemore DC, Bryans JS, Carnell P, Chessum NEA, Field MJ, Kinsella N, Kinsora JK, Osborne SA, Williams SC (2010) Synthesis and in vivo evaluation of 3-substituted gababutins. Bioorg Med Chem Lett 20(1): 362-365.
78. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DF, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC (1997) Synthesis and biological evaluation of the 1, 5,-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzemesulfonamide (SC-58635, Celecoxib). J Med Chem 40: 1347-1365.
79. Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC et al (1997) Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 121(1): 105-117.
80. Wei Q, Zhou DH, Shen QX, Chen J, Chen LW, Wang TL, Pei G, Chi ZQ (2000) Human mu-opioid receptor overexpressed in Sf9 insect cells functionally coupled to endogenous Gi/o proteins. Cell Res 10(2): 93-102.
81. Cashman JR, Ghirmai S (2009) Inhibition of serotonin and norepinephrin reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem 17: 6890-6897.
82. Jarvis MF, Khakh BS (2009) ATP-gated P2X cation channels. Neuropharmacology 56: 208-215.
83. Jacobson KA (2010) P2X and P2Y receptors. Tocris Biosci Sci Rev Ser 1: 15.
84. Gunosewoyo H, Kassiou M (2010) P2X purinergic receptor ligands: recently patented compounds. Exp Op Ther Pat 20(5): 625-646.
85. Jahangir A, Alam M, Carter DS, Dillon MP, Du Bois DJ, Ford APDW, Gever JR, Lin C, Wagner PJ, Zhai Y, Zira J (2009) Identification and SAR of novel diaminopyrimidines. Part 2: the discovery of RO-51, a potent and selective, dual P2X3/P2X2/3 antagonist for the treatment of pain. Bioorg Med Chem Lett 19: 1632-1635.
86. Brotherton-Pleiss CE, Dillon MP, Ford APDW, Gever JR, Carter DS, Gleason SK, Lin CJ, Moore AG, Thompson AW, Villa M, Zhai Y (2010) Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor anatagonist. Bioorg Med Chem Lett 20: 1031-1036.
87. Prous (2009) 659156. Available at http://. integrity. thomson-pharma. com. Drug Data Report 31(6): 538.
88. Prous (2010) 669469, 690966, 703690. Available at http://integrity. thomson-pharma. com. Drug Data Report 32(3): 241.
89. Shieh C-C, Jarvis MF, Lee C-H, Perner RJ (2006) P2X receptor ligands and pain. Exp Op Ther Pat 16(8): 1113-1127.
90. Jiang L-H, Mackenzie AB, North RA, Surprenant A (2000) Brilliant Blue G selectively blocks ATP-gated rat P2X7 receptors. Mol Pharmacol 58: 82-88.
91. Romagnoli R, Baraldi PG, Carrion MD, Cara CL, Preti D, Cruz-Lopez O, Tabrizi MA, Moorman AR, Gessi S, Fogli E, Sacchetto V, Borea PA (2007) From tyrosine to glycine: synthesis and biological activity of potent antagonists of the purinergic P2X7 receptor. J Med Chem 50(15): 3706-3715.
92. Romagnoli R, Baraldi PG, Cruz-Lopez O, Lopez-Cara C, Preti D, Borea PA, Gessi S (2008) The P2X7 receptor as a therapeutic target. Exp Op Ther Targ 12(5): 647-661.
93. Prous (2010) entry 669469. Available at http://integrity. thompsonpharma. com. Exp Pharmacol Rep.
94. Chen X, Pierce B, Naing W, Grapperhaus ML, Phillion DP (2010) Discovery of 2-chloro-N-((4, 4-difluoro-1-hydroxycyclohexyl)methyl)-5-(5-fluoropyrimidin-2-yl)benzamide as a potent and CNS penetrable P2X7 receptor antagonist. Bioorg Med Chem Lett 20(10): 3107-3111.
95. Prous (2010) entry 703690. Available at http://integrity. thompsonpharma. com. Exp Pharmacol Rep.